Free Trial
→ Satellite Images Spot Potential $10 Trillion Discovery (From Altimetry) (Ad)tc pixel Free EFTR Stock Alerts

eFFECTOR Therapeutics (EFTR) Competitors

eFFECTOR Therapeutics logo
$0.0005 +0.00 (+150.00%)
As of 01:20 PM Eastern
Compare

EFTR vs. ARDS, TRVN, NAVB, AMPE, and EVLO

Should you be buying eFFECTOR Therapeutics stock or one of its competitors? The main competitors of eFFECTOR Therapeutics include Aridis Pharmaceuticals (ARDS), Trevena (TRVN), Navidea Biopharmaceuticals (NAVB), Ampio Pharmaceuticals (AMPE), and Evelo Biosciences (EVLO). These companies are all part of the "pharmaceutical products" industry.

How does eFFECTOR Therapeutics compare to Aridis Pharmaceuticals?

eFFECTOR Therapeutics (NASDAQ:EFTR) and Aridis Pharmaceuticals (NASDAQ:ARDS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.

In the previous week, eFFECTOR Therapeutics' average media sentiment score of 0.00 equaled Aridis Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
eFFECTOR Therapeutics Neutral
Aridis Pharmaceuticals Neutral

57.7% of eFFECTOR Therapeutics shares are owned by institutional investors. Comparatively, 9.6% of Aridis Pharmaceuticals shares are owned by institutional investors. 4.7% of eFFECTOR Therapeutics shares are owned by company insiders. Comparatively, 5.5% of Aridis Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

eFFECTOR Therapeutics is trading at a lower price-to-earnings ratio than Aridis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
eFFECTOR TherapeuticsN/AN/A-$35.81M-$13.08N/A
Aridis PharmaceuticalsN/AN/A-$30.37M$0.090.00

Company Net Margins Return on Equity Return on Assets
eFFECTOR TherapeuticsN/A N/A N/A
Aridis Pharmaceuticals N/A N/A N/A

eFFECTOR Therapeutics has a beta of 2.41, meaning that its stock price is 141% more volatile than the S&P 500. Comparatively, Aridis Pharmaceuticals has a beta of 49.37, meaning that its stock price is 4,837% more volatile than the S&P 500.

Summary

Aridis Pharmaceuticals beats eFFECTOR Therapeutics on 5 of the 6 factors compared between the two stocks.

How does eFFECTOR Therapeutics compare to Trevena?

eFFECTOR Therapeutics (NASDAQ:EFTR) and Trevena (NASDAQ:TRVN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.

Company Net Margins Return on Equity Return on Assets
eFFECTOR TherapeuticsN/A N/A N/A
Trevena N/A N/A -119.55%

57.7% of eFFECTOR Therapeutics shares are held by institutional investors. Comparatively, 13.6% of Trevena shares are held by institutional investors. 4.7% of eFFECTOR Therapeutics shares are held by insiders. Comparatively, 2.7% of Trevena shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

eFFECTOR Therapeutics has higher earnings, but lower revenue than Trevena. Trevena is trading at a lower price-to-earnings ratio than eFFECTOR Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
eFFECTOR TherapeuticsN/AN/A-$35.81M-$13.08N/A
Trevena$443K0.02-$40.29M-$47.04N/A

eFFECTOR Therapeutics has a beta of 2.41, suggesting that its stock price is 141% more volatile than the S&P 500. Comparatively, Trevena has a beta of 0.56, suggesting that its stock price is 44% less volatile than the S&P 500.

In the previous week, eFFECTOR Therapeutics' average media sentiment score of 0.00 equaled Trevena'saverage media sentiment score.

Company Overall Sentiment
eFFECTOR Therapeutics Neutral
Trevena Neutral

Summary

eFFECTOR Therapeutics beats Trevena on 7 of the 8 factors compared between the two stocks.

How does eFFECTOR Therapeutics compare to Navidea Biopharmaceuticals?

eFFECTOR Therapeutics (NASDAQ:EFTR) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.

Company Net Margins Return on Equity Return on Assets
eFFECTOR TherapeuticsN/A N/A N/A
Navidea Biopharmaceuticals N/A N/A N/A

57.7% of eFFECTOR Therapeutics shares are held by institutional investors. Comparatively, 0.0% of Navidea Biopharmaceuticals shares are held by institutional investors. 4.7% of eFFECTOR Therapeutics shares are held by insiders. Comparatively, 43.7% of Navidea Biopharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Navidea Biopharmaceuticals has higher revenue and earnings than eFFECTOR Therapeutics. eFFECTOR Therapeutics is trading at a lower price-to-earnings ratio than Navidea Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
eFFECTOR TherapeuticsN/AN/A-$35.81M-$13.08N/A
Navidea Biopharmaceuticals$8.13K0.00-$15.18M-$0.21N/A

eFFECTOR Therapeutics has a beta of 2.41, suggesting that its stock price is 141% more volatile than the S&P 500. Comparatively, Navidea Biopharmaceuticals has a beta of 1.76, suggesting that its stock price is 76% more volatile than the S&P 500.

In the previous week, eFFECTOR Therapeutics' average media sentiment score of 0.00 equaled Navidea Biopharmaceuticals'average media sentiment score.

Company Overall Sentiment
eFFECTOR Therapeutics Neutral
Navidea Biopharmaceuticals Neutral

Summary

Navidea Biopharmaceuticals beats eFFECTOR Therapeutics on 4 of the 7 factors compared between the two stocks.

How does eFFECTOR Therapeutics compare to Ampio Pharmaceuticals?

Ampio Pharmaceuticals (NYSE:AMPE) and eFFECTOR Therapeutics (NASDAQ:EFTR) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, profitability, earnings, analyst recommendations and institutional ownership.

In the previous week, Ampio Pharmaceuticals had 1 more articles in the media than eFFECTOR Therapeutics. MarketBeat recorded 1 mentions for Ampio Pharmaceuticals and 0 mentions for eFFECTOR Therapeutics. Ampio Pharmaceuticals' average media sentiment score of 0.75 beat eFFECTOR Therapeutics' score of 0.00 indicating that Ampio Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
Ampio Pharmaceuticals Positive
eFFECTOR Therapeutics Neutral

Company Net Margins Return on Equity Return on Assets
Ampio PharmaceuticalsN/A N/A N/A
eFFECTOR Therapeutics N/A N/A N/A

5.7% of Ampio Pharmaceuticals shares are held by institutional investors. Comparatively, 57.7% of eFFECTOR Therapeutics shares are held by institutional investors. 3.3% of Ampio Pharmaceuticals shares are held by company insiders. Comparatively, 4.7% of eFFECTOR Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Ampio Pharmaceuticals has a beta of 5.96, meaning that its stock price is 496% more volatile than the S&P 500. Comparatively, eFFECTOR Therapeutics has a beta of 2.41, meaning that its stock price is 141% more volatile than the S&P 500.

Ampio Pharmaceuticals is trading at a lower price-to-earnings ratio than eFFECTOR Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ampio PharmaceuticalsN/AN/A-$8.63M-$11.01N/A
eFFECTOR TherapeuticsN/AN/A-$35.81M-$13.08N/A

Summary

Ampio Pharmaceuticals beats eFFECTOR Therapeutics on 5 of the 8 factors compared between the two stocks.

How does eFFECTOR Therapeutics compare to Evelo Biosciences?

Evelo Biosciences (NASDAQ:EVLO) and eFFECTOR Therapeutics (NASDAQ:EFTR) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, profitability, earnings, analyst recommendations and institutional ownership.

eFFECTOR Therapeutics is trading at a lower price-to-earnings ratio than Evelo Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evelo BiosciencesN/AN/A-$114.53M-$8.81N/A
eFFECTOR TherapeuticsN/AN/A-$35.81M-$13.08N/A

0.3% of Evelo Biosciences shares are held by institutional investors. Comparatively, 57.7% of eFFECTOR Therapeutics shares are held by institutional investors. 1.0% of Evelo Biosciences shares are held by company insiders. Comparatively, 4.7% of eFFECTOR Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Evelo Biosciences had 1 more articles in the media than eFFECTOR Therapeutics. MarketBeat recorded 1 mentions for Evelo Biosciences and 0 mentions for eFFECTOR Therapeutics. Evelo Biosciences' average media sentiment score of 0.00 equaled eFFECTOR Therapeutics'average media sentiment score.

Company Overall Sentiment
Evelo Biosciences Neutral
eFFECTOR Therapeutics Neutral

Company Net Margins Return on Equity Return on Assets
Evelo BiosciencesN/A N/A N/A
eFFECTOR Therapeutics N/A N/A N/A

Evelo Biosciences has a beta of 0.61, meaning that its stock price is 39% less volatile than the S&P 500. Comparatively, eFFECTOR Therapeutics has a beta of 2.41, meaning that its stock price is 141% more volatile than the S&P 500.

Summary

eFFECTOR Therapeutics beats Evelo Biosciences on 4 of the 7 factors compared between the two stocks.

Get eFFECTOR Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for EFTR and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EFTR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EFTR vs. The Competition

Export
MetriceFFECTOR TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$2K$897.39M$6.18B$12.29B
Dividend YieldN/A4.84%2.78%5.24%
P/E Ratio0.001.7128.7327.27
Price / SalesN/A122.44507.2964.11
Price / CashN/A20.0743.3053.97
Price / Book0.007.7110.006.83
Net Income-$35.81M-$5.06M$3.54B$332.87M
7 Day PerformanceN/AN/AN/A0.09%
1 Month PerformanceN/A51.50%4.66%7.36%
1 Year PerformanceN/A105.07%40.41%41.09%

eFFECTOR Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
EFTR
eFFECTOR Therapeutics
N/A$0.00
+150.0%		N/A+0.0%$2KN/AN/A10
ARDS
Aridis Pharmaceuticals
N/A$0.00
flat		N/A+3,000.0%$11KN/A0.0030
TRVN
Trevena
N/A$0.01
flat		N/A-99.0%$11K$443KN/A40
NAVB
Navidea Biopharmaceuticals
N/AN/AN/AN/A$10K$8.13KN/A10
AMPE
Ampio Pharmaceuticals
N/A$0.01
flat		N/A+23,603.7%$6KN/AN/A20

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:EFTR) was last updated on 5/8/2026 by MarketBeat.com Staff.
From Our Partners
One executive order. The biggest wealth transfer of your lifetime.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Satellite Images Spot Potential $10 Trillion Discovery
'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...
Altimetry | Sponsoredtc pixel
The Death of the Nasdaq?
The Death of the Nasdaq? Wall Street legend Marc Chaikin's award-winning system turned bearish on software ...
Chaikin Analytics | Sponsoredtc pixel
"Computers are about to become obsolete" - George Gilder. Here’s why.
George Gilder predicted the iPhone 16 years early, called Netflix a decade before it dominated streaming, and ...
Eagle Publishing | Sponsoredtc pixel
I’m sounding the alarm
Meta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...
Porter & Company | Sponsoredtc pixel
Nobody's Asking Where The SpaceX Money Comes From
When SpaceX goes public, fund managers will sell existing portfolio holdings to fund the move. Trillions in as...
Americas Gold Company | Sponsoredtc pixel
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel